Major US drugmaker MSD is to pay up to $1.3 billion to acquire CN201, a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated...
29.09.2017
- CMC Biologics, a wholly owned subsidiary of Japan’s Asahi Glass Company (AGC), will raise capacity at its site in Copenhagen, Denmark, to meet increasing demand for antibody drug...
26.07.2017
- Shire has obtained exclusive worldwide rights from Novimmune for a bi-specific antibody that is currently in pre-clinical development for treating patients with the blood disorders...
31.05.2017
- US drugmaker Merck has bought an exclusive global licence from Japan’s Teijin Pharma to develop, manufacture and commercialize an investigational preclinical antibody candidate...
21.03.2017
- UK medical research charity MRC Technology has licensed an antibody to Newsummit Biopharma, a leading Chinese drug developer, in an effort to create a novel therapeutic for...
28.02.2017
- UK pharmaceutical group Mundipharma is gearing up to launch Truxima (rituximab), a biosimilar from South Korea’s Celltrion, for the treatment of certain cancers and inflammatory...
24.01.2017
- US drugmaker Merck has settled its patent dispute with rival Bristol-Myers Squibb (BMS) and Japan’s Ono Pharmaceutical over cancer immunotherapy Keytruda. Under terms of the...
